A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds, lower heart-disease risk, manage obstructive sleep apnea, and more.But as more people use these ...

Women who take Wegovy to treat obesity have the greatest likelihood of achieving 10% or more weight loss in a ... which comes in a higher dose, is for weight loss while Victoza is for Type 2 diabetes.

Both drugs led to substantial weight loss, but Mounjaro's 20% weight reduction, after 72 weeks of treatment, exceeded the 14% from Wegovy. More in Health A 51-year-old says she's in the best shape ...

Wegovy is also effective within its approved use as a weight loss drug for adults with a body mass index over 27 and at least one health condition, such as high blood pressure, as well as adults ...

Fact checked by Jennifer Klump People who use Wegovy for weight management may be at higher risk for hair loss, according to a preprint study. Researchers found that people prescribed semaglutide ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Women with obesity and diabetes taking weight loss and diabetes drugs Mounjaro and Zepbound for over a year lost more weight than their male counterparts—but also experienced more nausea and ...

People considering weight-loss medications might wonder which one works best, and first-of-its-kind research points to an answer. A new study published in the New England Journal of Medicine ...